Following is a digest of pharmacogenomics journal articles pertaining to respiratory conditions.  The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.

Article Citation & LinkTypeMonthSNP•its Study Summary
Park HW et al. Pharmacogenomics in asthma therapy: where are we and where do we go? Annu Rev Pharmacol Toxicol. 2015;55:129-47.Review2015-09
Stettner M et al. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain Behav. 2015;
Wu AC et al. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Pharmacogenomics. 2015;16:591-600.Cost-effectiveness analysis2015-04
Stockmann C et al. Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. J Allergy Clin Immunol. 2015 Mar 27 [Epub ahead of print].Letter 2015-04
Lang JE et al. Lansoprazole is associated with worsening asthma control in children with the CYP2C19 poor metabolizer phenotype. Ann Am Thorac Soc.2015 Apr 16 [Epub ahead of print].Prospective Cohort2015-04
Carter S et al. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. J Cyst Fibr. 2015 Feb 16 [Epub ahead of print].Case Report2015-02
Pijnenburg MW et al. Personalized medicine in children with asthma. Paediatr Respir Rev. 2014 Nov 8 [Epub ahead of print].Review2014-11
De Lima Marson FA et al. Personalized drug therapy in cystic fibrosis: from fiction to reality. Curr Drug Targets. 2014 Nov 28 [Epub ahead of print].Perspective2014-11
McKone EF et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014 Oct 9 [Epub ahead of print].Phase 3, Open-Label Clinical Trail2014-10
Amaral MD. Novel personalized therapy for cystic fibrosis: treating the basic defect in all patients. J Intern Med. 2014 Sep 14 [Epub ahead of print].Review2014-09
Lima JJ. Do genetic polymorphisms alter patient response to inhaled bronchodilators? Expert Opin Drug Metab Toxicol. 2014;10:1231-40.Systematic review2014-09 
Ortega VE et al. Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management. Clin Genet. 2014;86:12-20.Review2014-07 
Meyers DA et al. Asthma genetics and personalized medicine. Lancet Respir Med. 2014;2:405-15.Commentary2014-05 
Karlin E et al. Genotyping for severe drug hypersensitivity. Curr Allergy Asthma Rep. 2014;14:418.Review2014-03 
Corvol H et al. Translating the genetics of cystic fibrosis to personalized medicine. Transl Res. 2015 Apr 15 [Epub ahead of print].Review2015-04
Lang JE et al., American Lung Association-Airways Clinical Research Centers. Lansoprazole Is associated with worsening asthma control in children with the CYP2C19 poor metabolizer phenotype. Ann Am Thorac Soc. 2015;12:878–85.Prospective Cohort2015-06
Moss RB et al., VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet. Resp Med. 2015;3:524-33.Double-blind, randomised controlled trial2015-07